WuXi AppTec Achieves Top Recognition in Extel 2025 Asia Executive Team Rankings

WuXi AppTec Earns Prestigious Recognition in the Extel 2025 Asia Executive Team Rankings

WuXi AppTec, a prominent global player offering a wide array of research and development (R&D) and manufacturing services, has recently garnered significant accolades in the Extel 2025 Asia Executive Team Rankings. This recognition places WuXi AppTec among the Top 10 “Most Honored Companies,” a classification that highlights its exceptional contributions to the pharmaceutical and life sciences sectors.

This recognition is particularly impressive considering WuXi AppTec was evaluated alongside over 1,600 companies spanning 18 different industries, showcasing the company's significant stature in the competitive market. The rankings are derived from a comprehensive survey conducted with investment professionals, affirming WuXi AppTec's commitment to improving patient care through innovative therapies globally.

Notably, WuXi AppTec achieved first place in five categories within the Healthcare and Pharma Biotech sector, namely, “Best CEO,” “Best CFO,” “Best Company Board,” “Best IR Program,” and “Best ESG Program.” These accolades resonate not only as a reflection of the firm's internal governance and leadership but also highlight its focus on sustainability, ethical practices, and impeccable investor relations.

The Extel rankings, an annual survey, have established themselves as a reliable benchmark in the global capital markets. This year, more than 6,300 portfolio managers and analysts across 1,324 institutions—comprising 1,167 buy-side firms and 157 sell-side firms—took part in the survey, which evaluated and rated 1,668 companies and engaged 2,367 executives. This level of scrutiny demonstrates WuXi AppTec's significance as a trusted partner in the healthcare landscape.

WuXi AppTec is dedicated to enabling its customers to bring cutting-edge care to patients by aligning its services with customer needs, driving scientific innovation, and seizing new molecular opportunities. The company's unique Contract Research, Development, and Manufacturing Organization (CRDMO) model provides comprehensive support throughout the drug development process. Not only does this model streamline operations, but it also significantly reduces costs associated with research and implementation, all while adhering to the highest standards of quality management.

Established with a global footprint across Asia, Europe, and North America, WuXi AppTec's services are integral to advancing discoveries and delivering groundbreaking treatments. The organization’s extensive portfolio includes chemistry drug CRDMO, biology discovery, and preclinical and clinical research services. These integrated offerings facilitate the success of their clients in pushing the boundaries of healthcare with cost-effective and efficient solutions.

In 2024, WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year, an affirmation of its commitment to sustainable practices. Furthermore, its open-access platform empowers around 6,000 clients from more than 30 countries, amplifying the company’s vision that “every drug can be made and every disease can be treated.” Through these initiatives, WuXi AppTec continues to contribute significantly to the global health care landscape.

As it enhances its services and builds on its accolades, WuXi AppTec reaffirms its commitment to maintaining high-quality standards, integrity, and delivering exceptional value to stakeholders, proving its pivotal role in the advancement of pharmaceutical innovation.